Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average) (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Shares Outstanding (Weighted Average) data on record, last reported at $82.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 19.49% year-over-year to $82.9 million; the TTM value through Dec 2025 reached $82.9 million, up 19.49%, while the annual FY2025 figure was $82.9 million, 19.49% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $82.9 million in Q4 2025 per CCCC's latest filing, up from $72.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $82.9 million in Q4 2025 and bottomed at $43.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $57.1 million, with a median of $49.1 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 2845.46% in 2021, then grew 0.49% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46.0 million in 2021, then increased by 6.12% to $48.9 million in 2022, then increased by 1.59% to $49.6 million in 2023, then surged by 39.75% to $69.4 million in 2024, then increased by 19.49% to $82.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $82.9 million in Q4 2025, $72.6 million in Q3 2025, and $70.9 million in Q2 2025.